Dishman Carbogen Amcis Ltd.
Snapshot View

209.20 +0.10 â–˛0.1%

30 July 2021, 04:00:00 P.M.
Volume: 54,603

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.dishmangroup.com
Financial Indicators
Market Cap 3,279.90 Cr.
Earnings per share (EPS) -10.53 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) - Trailing Twelve Months Ending 2021-03
Industry PE 34.39 Trailing Twelve Months Ending 2021-03
Book Value / Share 363.48 Trailing Twelve Months Ending 2021-03
Price to Book Value 0.58 Calculated using Price: 209.20
Dividend Yield 0.00 Period Ending 2021-03
No. of Shares Subscribed 15.68 Cr. 156,783,095 Shares
FaceValue 2
Company Profile

Incorporated in 1983, Dishman Carbogen Amcis Limited (DCAL) started out as a manufacturer of quaternary ammonium and phosphate compounds. Having ventured into the CRAMS space in India, the company soon became one of the fastest growing companies. Today, the company is a leading global outsourcing partner for the pharmaceutical industry, offering a portfolio of development, scale-up, and manufacturing services.

The company aids drug innovators for development and process optimization for novel drug molecules in various stages of the development process. Once the innovative molecules are approved, the company further explore the possibility of large scale commercial supply tie-ups. The company is generating a healthy pipeline of contract manufacturing opportunities commensurate to the growing revenue base of manufacturing. Its robust business model is capable of sustaining growth, with CRAMS being the focal point of all its strategic efforts.

Business area of the company

The company is a fully integrated CRAMS player working with global pharmaceutical innovators. It has a global presence with development and manufacturing facilities across Europe, India, and China. It provides end-to-end, integrated, high-value, niche CRAMS offering, right from process research & development to late-stage clinical and commercial manufacturing facilities along with the supply of Active Pharmaceutical Ingredients (API) to innovator pharmaceutical companies.

Products and services

  • CRAMS
  • Vitamin D & Analogues
  • Disinfectants
  • Highly Potent API Supply
  • Niche Generic API
  • Speciality Chemicals

History and Milestones

  • 1983: Incorporation of Dishman Pharmaceutical and Chemicals Limited.
  • 1989: Commencing production of Phase Transfer Catalysts at Naroda facility.
  • 1995: Entered into a JV with Schutz & Co. for manufacturing Chlorhexidine and Derivatives for European market.
  • 1996: Commencement of Bavla facility for Bulk Intermediates.
  • 2001: First commercial contract manufacturing agreement signed with a major western pharmaceutical company.
  • 2004: Came out with an IPO on Indian stock exchanges.
  • 2005: Acquisition of Synprotec - DCR (now known as CARBOGEN AMCIS Ltd, UK).
  • 2006: Acquisition of CARBOGEN AMCIS - a Swiss based CRAMS player.
  • 2007: Acquisition of Solvay Pharmaceuticals’ Vitamins and Chemicals business (now known as CARBOGEN AMCIS BV).
  • 2010: Commenced Dishman Shanghai manufacturing facility.
  • 2012: Acquisition of Riom (France) - CARBOGEN AMCIS SAS.
  • 2014: Acquisition of Vionnaz (CH) site - CARBOGEN AMCIS.
  • 2017: Change of name of the parent to Dishman Carbogen Amcis Limited, reinforcing the synergies between Dishman and Carbogen Amcis brands.
  • 2020: Global Reorganization of Roles and Responsibilities of the Management Team.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+0.05%
1 Week
+0.36%
1 Month
-2.49%
3 Month
+32.83%
6 Month
+70.57%
1 Year
+11.75%
2 Year
+0.50%
5 Year
5 years 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) 3,676.38 6.05 4.01 2.86 -2.89
Return on Capital Employed (%) 4.61 4.67 5.79 3.93 -0.26
Return on Assets (%) 2.23 2.25 2.90 2.04 -2.00

Balance Sheet View Details

Particulars 5 years 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Shh. Funds 4,814 5,107 5,379 5,715 5,699
Non Curr. Liab. 767 884 743 909 1,367
Curr. Liab. 994 1,178 1,198 1,569 1,249
Minority Int.
Equity & Liab. 6,574 7,169 7,321 8,193 8,314
Non Curr. Assets 5,241 5,623 5,767 6,414 6,652
Curr. Assets 1,333 1,546 1,554 1,779 1,663
Misc. Exp. not W/O
Total Assets 6,574 7,169 7,321 8,193 8,314

Profit Loss View Details

Particulars 5 years 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Net Sales 1,714 1,695 2,059 2,044 1,912
Other Income 26 53 54 44 38
Total Income 1,740 1,748 2,112 2,088 1,950
Total Expenditure -1,260 -1,257 -1,507 -1,546 -1,638
PBIDT 479 491 606 542 313
Interest -49 -49 -57 -62 -48
Depreciation -214 -211 -240 -283 -308
Taxation -71 -76 -98 -39 -100
Exceptional Items -22
PAT 146 155 210 159 -165

Cash Flow View Details

Particulars 5 years 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. 303 226 282 585 513
Cash Fr. Inv. -142 -297 -169 -442 -381
Cash Fr. Finan. -137 78 -102 -98 -11
Net Change 23 7 11 46 122
Cash & Cash Eqvt 59 66 76 122 244

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 61.40 61.40 61.40 63.17 63.21 63.21 61.93 59.32 59.32
Public 38.60 38.60 38.60 36.83 36.79 36.79 38.07 40.68 40.68
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Wed, 21 Jul 2021
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
We hereby inform you that the 14th Annual General Meeting of the Company held on Monday 19th July 2021 was commenced at 03:00 P.M. IST through Video Conferencing.

In this regard please find enclosed herewith Scrutinizers Report dated 20th July 2021 issued by M/s. Ashok P. Pathak & Co. Practicing Company Secretaries Ahmedabad on the results of the voting through remote e-Voting and e-voting during AGM in respect of agenda items set out in Notice dated 16th June 2021 of 14th AGM of the Company.
Wed, 21 Jul 2021
Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations 2015)
Dishman Carbogen Amcis Ltd has informed BSE regarding the details of Voting results of AGM under Regulation 44(3) of SEBI (LODR) Regulations 2015. Kindly Click here
Tue, 20 Jul 2021
Shareholder Meeting / Postal Ballot-Outcome of AGM
In terms of Regulation 30 read with para A of part A of Schedule III of SEBI (LODR) Regulations 2015 please find attached herewith the proceedings of the 14th Annual General Meeting.

Technical Scans View Details

Thu, 29 Jul 2021
Close Within 2 Year High Zone Close Within 2 Year High Zone
Both SRS And ARS Above Zero Both SRS And ARS Above Zero
5 EMA Crossing 20 EMA From Above 5 EMA Crossing 20 EMA From Above
Wed, 28 Jul 2021
Decreasing Relative Strength - Benchmark index Decreasing Relative Strength - Benchmark index
Decreasing Relative Strength - Sectoral index Decreasing Relative Strength - Sectoral index

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 168,733.23 774.00 +10.1%
Divi's Laboratories Ltd. 128,656.69 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. 77,707.65 4,712.70 +0.9%
Cipla Ltd. 71,170.06 920.30 +4.3%
Cadila Healthcare Ltd. 58,547.84 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. 58,067.43 4,025.00 -0.3%
Aurobindo Pharma Ltd. 53,214.94 916.50 +0.9%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 58.11 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2021-03 64.84 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 44.73 4,712.70 +0.9%
Cipla Ltd. Consolidated 2021-03 29.59 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 27.44 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 386.19 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2021-03 9.98 916.50 +0.9%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 3.63 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2021-03 13.84 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 4.35 4,712.70 +0.9%
Cipla Ltd. Consolidated 2021-03 3.88 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 4.51 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.64 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.43 916.50 +0.9%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 0.18 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 916.50 +0.9%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 10.09 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 916.50 +0.9%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 12.53 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 916.50 +0.9%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 17,131.99 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 916.50 +0.9%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 1,546.98 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 916.50 +0.9%